Evidence map›Paper›PMID 17203107›Full record

ArticleGene therapy2007

Construction and characterization of efficient, stable and safe replication-deficient foamy virus vectors.

P Bastone, F Romen, W Liu, R Wirtz, U Koch, N Josephson, S Langbein, M Löchelt

Abstract read
PubMed Publisher
In one paragraph

Article in Gene therapy, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Foamy virus vectors for gene transfer.Expert opinion on biological therapy · 2009
    Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 3 countries.

P BastoneAbt. Genomveränderungen und Karzinogenese, Forschungsschwerpunkt Infektion und Krebs, Deutsches Krebsforschungszentrum, Heidelberg, Germany.
F Romen
W Liu
R Wirtz
U Koch
N Josephson
S Langbein
M Löchelt
German Cancer Research Center · DEDKFZ-ZMBH Alliance · DEBloodworks Northwest · USUniversity of Amsterdam · NL

Funding

T-CELL IMMUNE RESPONSES TO FACTOR VIIIP50HL081015 · NHLBI · PUGET SOUND BLOOD CENTER · PI SLICHTER, SHERRILL J. · 2005 to 2009
$10.1M
NHLBI NIH HHS P50 HL081015
6 · The paper itself

Abstract

As serious side effects affected recent virus-mediated gene transfer studies, novel vectors with improved safety profiles are urgently needed. In the present study, replication-deficient retroviral vectors based on feline foamy virus (FFV) were constructed and analyzed. The novel FFV vectors are devoid of almost the complete env gene plus the internal promoter - accessory bel gene cassette including the gene for the viral transcriptional transactivator Bel1/Tas. In these Bel1/Tas-independent vectors, expression of the lacZ (beta-galactosidase) marker gene is directed by the heterologous, constitutively active human ubiquitin C promoter (ubi). Env-transcomplemented vectors have un-concentrated titers of more than 10(5) transducing units/ml. The vectors allow efficient transduction of a broad array of diverse target cells, which can be increased by repeated vector exposure. However, the number of lacZ marker gene expressing cells decreased slightly upon serial passages of the transduced cells. Vectors carrying a self-inactivating (SIN) deletion of the TATA box and most parts of the viral promoter were not rescued by wt FFV whereas those with the intact or a partially deleted promoter were readily reactivated. This finding indicates that the viral promoters are in fact non-functional, pointing to a highly advantageous safety profile of these new FFV-ubi-lacZ-SIN vectors.

Indexed as

Genetic TherapyAnimalsCatsCell LineCloning, MolecularCricetinaeDogsGene DeletionGenetic EngineeringGenetic VectorsHumansMiceRecombinant Fusion ProteinsSafetySheepSpecies SpecificityRecombinant Fusion ProteinsViral Envelope ProteinsViral Vaccines

Identifiers

PMID17203107
OpenAlexW2003847421

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.